For patients with inflammatory bowel disease (IBD), symptoms of active disease can be challenging and life-altering. But a new treatment could offer hope.
The BOOM-IBD trial, led by colorectal surgeon Marco B. Zoccali, MD, is investigating sacral nerve stimulation (SNS) as a novel therapy for IBD patients struggling with poorly controlled symptoms. After promising results in the early feasibility phase, the pivotal trial is now officially open for enrollment.
What is Sacral Nerve Stimulation?
Sacral nerve stimulation works by modulating the nerve signals that control bowel function. While already FDA-approved for fecal incontinence and overactive bladder, this study aims to determine whether it could also benefit IBD patients dealing with persistent disease activity and its debilitating symptoms.
Who Can Enroll?
The trial is open to eligible ulcerative colitis patients with symptomatic, mild to moderately active disease despite standard treatments. If you've been searching for a new approach to symptom relief, this study may be an option.
How to Participate
The pivotal trial is currently accepting patients for screening. Click here to learn more about trial enrollment and eligibility.
Enrollment Contact:
Call (212) 342-4102
Shivani Guha: sg4365@cumc.columbia.edu
Claudia Musat, MD: cm2065@cumc.columbia.edu
Related:
- Dr. Marco Zoccali Explains Groundbreaking Clinical Trial for IBD
- How a New Clinical Trial for IBD Is Changing Frank’s Life
- State of the Union Conversation: The Columbia Global Center for Integrated Colorectal Surgery & IBD Interventional Endoscopy